BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 21715011)

  • 1. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
    Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
    Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
    Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
    Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
    Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
    Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
    Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
    Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
    Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
    Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.
    Bhisitkul RB; Campochiaro PA; Shapiro H; Rubio RG
    Ophthalmology; 2013 May; 120(5):1057-63. PubMed ID: 23415775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
    Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
    Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
    Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
    Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
    Haller JA; Bandello F; Belfort R; Blumenkranz MS; Gillies M; Heier J; Loewenstein A; Yoon YH; Jacques ML; Jiao J; Li XY; Whitcup SM;
    Ophthalmology; 2010 Jun; 117(6):1134-1146.e3. PubMed ID: 20417567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.